EUVIMEDEUVIMED entdecken
Multizentrische Studie

The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis

Takanori Suzuki, Ryo Sato, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Atsunori Kusakabe, Izumi Hasegawa, Kiyoto Narita, Tsutomu Mizoshita und 9 weitere

Oncology · 11.05.2026 · 1-11

DOI: 10.1159/000552397 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology, online erschienen am 11.05.2026. Verfasst von Takanori Suzuki und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Bevacizumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Therapeutic response in patients with unresectable hepatocellular carcinoma (HCC) receiving multikinase inhibitors is associated with changes in liver function. However, limited data are available for patients treated with atezolizumab plus bevacizumab (ATZ/BEV).

Methods

We retrospectively enrolled 151 patients with unresectable HCC who received ATZ/BEV as first-line systemic therapy. Liver function was assessed using albumin-bilirubin (ALBI) score at baseline (pre-ALBI) and 6 weeks after the initiation of ATZ/BEV (6W-ALBI). We evaluated the dynamic relationship between initial therapeutic response and changes in ALBI score (6W-ALBI − pre-ALBI), and examined the prognostic impact of pre-ALBI, 6W-ALBI, and ALBI score changes.

Results

Patients achieving an initial complete or partial response (CR+PR) showed a significantly higher rate of improvement in ALBI score from baseline to 6W after the initiation of ATZ/BEV than those with stable or progressive disease (SD+PD) at the initial treatment response (46% vs. 25%, respectively, p = 0.018). Among patients with baseline ALBI grade ≥2, changes in ALBI score differed significantly between the groups (median change: CR+PR vs. SD+PD, −0.03 vs. 0.18, respectively, p = 0.048). Time-dependent receiver operating characteristic analysis demonstrated 6W-ALBI had the best predictive ability for overall survival (OS) at 12 months after the ATZ/BEV initiation (optimal cutoff −1.95, area under the curve: 0.763). Using this cutoff, 6W-ALBI was independently associated with OS in multivariate analysis (hazard ratio: 2.40, p = 0.004).

Conclusions

Initial therapeutic response to ATZ/BEV was associated with changes in liver function. The ALBI score during ATZ/BEV may serve as a prognostic indicator.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularBevacizumabAntineoplastic Combined Chemotherapy ProtocolsLiverHumansFemaleMaleAntibodies, Monoclonal, HumanizedRetrospective StudiesAgedMiddle AgedPrognosisTreatment OutcomeBilirubinAged, 80 and over

Stichwörter der Autor:innen

Atezolizumab plus bevacizumabHepatocellular carcinomaTherapeutic response

Substanzen

BevacizumabAntibodies, Monoclonal, HumanizedatezolizumabBilirubin

Autor:innen und Institutionen

  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Gastroenterology, Nagoya City University, East Medical Center, Nagoya, Japan.
  • Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, matsuura@med.nagoya-cu.ac.jp.
  • Department of Gastroenterology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
  • Department of Gastroenterology, Gifu Prefectural Tajimi Hospital, Gifu, Japan.
  • Department of Gastroenterology, Kasugai Municipal Hospital, Kasugai, Japan.

Zitieren

APA

Suzuki, T., Sato, R., Matsuura, K., Kato, D., Hayashi, K., Okayama, K., Okumura, F., Sobue, S., Kusakabe, A., Hasegawa, I., Narita, K., Mizoshita, T., Kimura, Y., Kondo, H., Kojima, H., Hayashi, K., Ozasa, A., Kawamura, H., Fujiwara, K., …, & Kataoka, H. (2026). The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis. Oncology, 1-11. https://doi.org/10.1159/000552397

Vancouver

Suzuki T, Sato R, Matsuura K, Kato D, Hayashi K, Okayama K, et al. The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis. Oncology. 2026:1-11. doi:10.1159/000552397

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Takanori and Sato, Ryo and Matsuura, Kentaro and Kato, Daisuke and Hayashi, Katsumi and Okayama, Kohei and Okumura, Fumihiro and Sobue, Satoshi and Kusakabe, Atsunori and Hasegawa, Izumi and Narita, Kiyoto and Mizoshita, Tsutomu and Kimura, Yoshihide and Kondo, Hiromu and Kojima, Hisayo and Hayashi, Kazuki and Ozasa, Atsushi and Kawamura, Hayato and Fujiwara, Kei and Nojiri, Shunsuke and Kataoka, Hiromi},
  title = {The Initial Therapeutic Response in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Contributes to the Change of Liver Function during Treatment: A Multicenter Analysis},
  journal = {Oncology},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000552397}
}
Kostenlos starten →